This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Destiny Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Destiny Pharma şirketinin toplam hissedar öz sermayesi £9.2M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £10.0M ve £768.3K dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£6.38m
Eşitlik	UK£9.19m
Toplam yükümlülükler	UK£768.32k
Toplam varlıklar	UK£9.96m

Son finansal sağlık güncellemeleri

Recent updates

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Jan 12

Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

Sep 26

We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

May 26

Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Feb 01

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Aug 05

Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Apr 16

What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

Feb 11

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Nov 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DEST 'nin kısa vadeli varlıkları ( £7.6M ) kısa vadeli yükümlülüklerini ( £768.3K ) aşıyor.

Uzun Vadeli Yükümlülükler: DEST un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DEST borçsuzdur.

Borcun Azaltılması: DEST son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DEST şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: DEST un, serbest nakit akışı her yıl % 7.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company listing is no longer active

Destiny Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Destiny Pharma plc Announces Last Day of Dealings on AIM

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Recent updates

Destiny Pharma Initiates Research to Explore XF Drug Potential for CF

Destiny Pharma plc Announces Last Day of Dealings on AIM

Price target increased by 29% to UK£2.60

Destiny Pharma plc Announces New Clinical Data from its Phase 2b Clinical Trial on XF-73 in Cardiovascular Surgery Patients

New major risk - Financial position

Destiny Pharma plc Receives Innovation Passport Designation by the UK MHRA for XF-73 Nasal for the Prevention of Post-Surgical Site Infections

Price target increased by 29% to UK£2.60

Destiny Pharma plc, Annual General Meeting, Jun 12, 2024

Destiny Pharma plc to Report Fiscal Year 2023 Results on Apr 25, 2024

Price target increased by 41% to UK£2.82

Destiny Pharma plc Announces Clinical Development Update Positive Results from XF-73 Dermal Safety Study

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Price target increased by 41% to UK£2.82

New major risk - Share price stability

Destiny Pharma plc Announces the Publication of New Microbiological Data on Xf-73 (Exeporfinium Chloride), Its Leading Antibacterial Drug,In Frontiers in Cellular and Infection Microbiology

Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

Destiny Pharma plc to Report First Half, 2023 Results on Sep 20, 2023

Destiny Pharma plc Appoints Sir Nigel Rudd as New Chairman

Destiny Pharma plc Announces Departure of Nick Rodgers as Chairman

Destiny Pharma plc Confirms Proposed Phase 3 Development Pathway and Identifies New Life Cycle Management Targets for XF-73 Nasal

We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

Destiny Pharma plc Announces CEO Changes

Price target increased by 34% to UK£2.70

Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Destiny Pharma plc Announces Finalisation of its Phase 3 Development Plans for XF-73 Nasal

Less than half of directors are independent

Price target increased to UK£2.50

Destiny Pharma plc Positive update from EMA on NTCD-M3 Phase 3 plans

Destiny Pharma plc to Report First Half, 2022 Results on Sep 08, 2022

Destiny Pharma plc Announces Publication of New Data on NTCD-M3

Destiny Pharma plc Receives Positive Feedback from the U.S. Food and Drug Administration

Destiny Pharma plc Announces Publication of XF-73 Drug Synergy Data

Destiny Pharma plc Starts New Research Programme

Destiny Pharma plc Announces Board Changes

Destiny Pharma plc Announces Landmark NTCD-M3 Data to Be Presented At Anaerobe

Destiny Pharma plc Appoints Yuri Martina as Chief Medical Officer

Price target decreased to UK£3.06

Less than half of directors are independent

Destiny Pharma plc to Report Fiscal Year 2021 Results on Apr 12, 2022

Price target decreased to UK£3.06

Destiny Pharma plc Receives Positive Scientific Advice from the European Medicines Agency

Destiny Pharma plc Announces Positive Results in XF-73 Dermal Safety Study from Ongoing Agreement with US Government's NIAID

Destiny Pharma plc Announces Successful Outcome of Cooperative R&D Agreement with US Department of Veterans Affairs with NTCD-M3

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Founder recently sold UK£420k worth of stock

Destiny Pharma plc Announces XF-73 Data Abstract to Be Presented At 2021 ECCMID

Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Destiny Pharma plc to Report Fiscal Year 2020 Results on Apr 14, 2021

Destiny Pharma Announces Agreement with NIAID to Evaluate A Novel XF-73 Formulation in Skin Wound Infection

New 90-day high: UK£1.33

What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

New 90-day high: UK£1.27

Destiny Pharma plc Announces the Appointment of Mark Wilcox to its Scientific Advisory Board

New 90-day high: UK£1.13

Destiny Pharma Appoints Stephanie Bewick as CBO

Destiny Pharma plc Completes Phase 2b Trial of XF-73 Recruitment

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

New 90-day high: UK£0.88

Destiny Pharma plc Announces Clinical Study Patient Recruitment Update

New 90-day high: UK£0.65

Destiny Pharma plc to Report First Half, 2020 Results on Sep 17, 2020

New 90-day high - UK£0.59

New 90-day low - UK£0.31

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin